PT-141 Therapy

PT-141 is a melanocortin receptor agonist that primarily activates the MC4R receptor in the hypothalamus and limbic system, areas of the brain directly involved in sexual arousal and desire. By stimulating these central nervous system pathways, PT-141 initiates a cascade of neurochemical signaling that enhances libido and sexual motivation through dopaminergic mechanisms. This is fundamentally different from vascular agents, which work by increasing blood flow to genital tissues. The peptide's action on central arousal pathways means it may be effective for desire-based concerns that do not respond to peripherally-acting agents.

PT-141 is commonly sought by both men and women experiencing reduced sexual desire that has not responded to other approaches. Women with hypoactive sexual desire disorder represent the FDA-approved indication, but many clinics also provide it for men. Patients who have not found vascular-focused solutions effective for their concerns, or who identify their primary issue as desire rather than function, are particularly likely to seek PT-141.

PT-141 is administered via subcutaneous injection, typically in the abdomen, approximately 45 minutes before anticipated sexual activity. It is used on an as-needed basis rather than daily. Most providers recommend limiting use to no more than once in a 24-hour period and no more than eight doses per month to maintain effectiveness and minimize side effects.